Heron Shares Jump After Equity Financing, Q2 Earnings

  • Heron Therapeutics Inc HRTX reported Q2 sales of $27.63 million, +23.1% Y/Y, beating the consensus of $24.31 million. 
  • Oncology sales reached $25.1 million, up from $22.4 million a year ago.
  • The company reported an EPS loss of $(0.55), narrower from $(0.62) a year ago but missing the consensus of $(0.50).
  • In June 2022, Heron announced a corporate restructuring and cost reduction plan. It expects to achieve over $50 million in reductions in annual operating expenses in 2023.
  • The company announced a private placement of 16.13 million at $3.10 per share and pre-funded warrants to purchase up to 8.5 million shares at $3.0999 per pre-funded warrant.
  • Gross proceeds of the private placement are expected to be approximately $76.5 million.
  • With the proceeds from the recent private placement, pro-forma cash at the end of the second quarter was $158.7 million, which is projected to provide a cash runway through 2024.
  • Guidance: Heron currently expects FY22 oncology sales of $93-$95 million, up from prior guidance of $89-$93 million.
  • Price Action: HRTX shares are up 16.2% at $4.15 during the market session on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: BiotechEarningsNewsPenny StocksHealth CareFinancingOfferingsSmall CapMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!